Cardiovascular and Metabolic Disorders

Latest News

Bariatric Surgery Linked to Longer Life Expectancy in Obesity

Bariatric surgery is associated with longer life expectancy than usual care among patients with obesity.

The Lipid Paradox and CVD Risk in Rheumatoid Arthritis

By

Tori Rodriguez, MA, LPC, AHC

Mechanistic and outcomes studies are warranted to elucidate the lipid paradox and CVD risk in rheumatoid arthritis (RA).

Metabolic Surgery May Cut Risk for Cardiovascular Events, Death

Metabolic surgery for patients with morbid obesity and pharmacologically treated hypertension is associated with a lower risk for MACE and all-cause mortality vs individuals with hypertension from the general population.

Empagliflozin Fast Tracked for Improving Outcomes Following Myocardial Infarction

By

Brian Park, PharmD

The effect of empagliflozin on all-cause mortality and hospitalization for heart failure will be evaluated in the in phase 3 EMPACT-MI study.

Risk Factors for Cardiometabolic Disease in Those Taking Opioids

By

Jessica Nye, PhD

Researchers used data from the National Health and Nutrition Examination Survey 2009-2018 to assess the impact of drug and alcohol use on cardiometabolic disease risk factors.

HDL Cholesterol Efflux May Be Impaired in Severe Short-Term Hypothyroidism

By

Amit Akirov, MD

High-density lipoprotein cholesterol efflux capacity may be impaired in patients with severe short-term hypothyroidism.

Neuropsychiatric Disorders Increased in Children of Those With PCOS

Exposure to maternal polycystic ovary syndrome (PCOS) is associated with increased risk of a range of neurodevelopmental and psychiatric disorders in offspring.

Baseline TAG Levels Independently Associated With Adverse CV Outcomes in T2DM

By

Madeline Morr

Researchers sought to determine whether triglyceride levels were independently associated with cardiovascular disease among patients with coronary artery disease and type 2 diabetes.

Evolocumab Reduces LDL-C in Pediatric Heterozygous FH

By

Brian Park, PharmD

The multicenter, double-blind, placebo-controlled HAUSER-RCT study assessed the efficacy and safety of evolocumab in 157 patients aged 10 to 17 years with HeFH.

Metabolic Syndrome Linked to Worse Outcomes in COVID-19

Metabolic syndrome (MetS) is associated with a lethal outcome for patients with COVID-19.

Consistent LDL-C Lowering Reported With Twice-Yearly Inclisiran

By

Brian Park, PharmD

The post-hoc analysis included 2 placebo-controlled phase 3 studies (ORION-10 and -11) that evaluated the efficacy and safety of inclisiran sodium in more than 2300 adult patients.